#USA #Nashville #medical technology #Phagenesis #Stephen Oesterle

Phagenesis Welcomes Stephen Oesterle, MD, to Its Board of Directors

Phagenesis, a company at the forefront of developing neuromodulation therapies aimed at treating swallowing disorders, has announced a significant leadership change. On April 29, 2026, the company revealed the appointment of Dr. Stephen N. Oesterle to its Board of Directors. His extensive experience in the medical technology arena is expected to steer Phagenesis through its next critical phase of growth.

Who is Stephen Oesterle?

Dr. Oesterle is a highly esteemed figure within the medical technology and life sciences sectors. With a career spanning several decades, he has gathered a wealth of expertise across clinical medicine, strategic corporate planning, and venture investments. Prior to this, he held the position of Senior Vice President for Medicine and Technology at Medtronic, a role he occupied for 14 years on the company's Executive Committee. During his tenure, he was instrumental in shaping long-term innovation strategies and making pivotal corporate investments.

“I am excited to join the Phagenesis Board at a pivotal moment in the company's evolution,” remarked Dr. Oesterle. “Phagenesis has built a strong clinical foundation and is addressing a significant unmet need in patient care.” His balance of clinical acumen and strategic foresight is expected to bolster the company's trajectory towards becoming a leader in swallowing disorder therapies.

Supporting Growth and Innovation

Chairman of the Board, Oern Stuge, expressed enthusiasm over Oesterle’s appointment, stating, “Steve brings deep experience in medical technology across many applications and has experience from companies that successfully navigate critical growth stages.” This indicates a strategic move by Phagenesis to reinforce its Board with talent that can guide the company through the complexities of market expansion and product development.

Oesterle’s background includes roles on the boards of Baxter and Peijia Medical, alongside several private equity and venture-capital-backed healthcare ventures. His advisory connections with prominent investment firms such as EQT, Novo Holdings, and JP Morgan Life Sciences further endorse his industry influence and strategic insight.

Phagenesis aims to capitalize on the rising recognition of their pharyngeal electrical stimulation (PES) technology, which has been cited as an effective intervention for severe dysphagia, particularly post-stroke. The recent endorsement from the American Heart Association/American Stroke Association—listing PES as a clinically validated therapy—marks a key milestone for the company, underscoring the therapy’s significance in improving patient outcomes.

The Future of Phagenesis

The appointment comes as Phagenesis gears up for broader market adoption in the U.S. Following a successful phase of initial commercialization, the company is focusing on increasing clinical use of the Phagenyx® System, which provides pharyngeal electrical stimulation to enhance swallowing safety and efficiency. Oesterle's insight and prior experience are anticipated to play a crucial role as Phagenesis looks to deepen clinical adoption and enhance the standard of care for swallowing disorders.

As Phagenesis continues its ambitious plans for global expansion, Oesterle emphasized the importance of making a difference in patient care, particularly for those suffering from severe dysphagia. “The opportunity to improve outcomes for patients while alleviating the cost and complexity for healthcare systems is compelling,” he stated.

In conclusion, Dr. Stephen Oesterle’s addition to the Board of Phagenesis symbolizes a strategic alignment with the company’s vision for growth and innovation in the neuromodulation space, as it aspires to establish itself as a key player in the treatment of swallowing disorders worldwide. With this new leadership, Phagenesis is poised to accelerate its mission and impact significantly, ensuring that advances in technology translate to better health outcomes for patients across the globe.